Pharma

Revolution Medicines booth at ASCO 2026
Favicon Fierce Pharma

FDA greenlights RevMed’s pancreatic cancer gamechanger

Following dynamite data that earned a standing ovation at ASCO, RevMed's star Ras inhibitor daraxonrasib has been approved by the FDA.
Darren Incorvaia Aug 26, 2026 11:30am
Akeso
Favicon Fierce Pharma

Akeso CEO touts biliary tract win, counters ivonescimab debate

Aug 26, 2026 11:11am
Goal disorientation and lack of vision

Spyre’s rheumatoid arthritis plan toppled by subpar TL1A data

Aug 26, 2026 5:40am
Deal

SK's $795M deal to usher Biohaven’s epilepsy therapy towards FDA

Aug 26, 2026 4:47am
Connection together puzzle pieces Concept of business strategy collaboration
Favicon Fierce Pharma

McKesson acquires Maryland CRO for $2.25 billion

Aug 25, 2026 11:22am
Three blocks displaying from left to right a person a handshake and another person

Metsera duo power Sentivera to $1.5B inflammatory disease deal

Aug 25, 2026 9:24am